• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Zoll Medical wins CE Mark for oxygen therapy system

Zoll Medical wins CE Mark for oxygen therapy system

May 4, 2020 By Sean Whooley

Zoll Medical announced today that it received CE Mark approval in Europe for its TherOx SuperSaturated Oxygen (SSO2) therapy system.

SSO2 therapy offers interventional cardiologists a treatment beyond percutaneous coronary intervention (PCI) that significantly reduces muscle damage in heart attack patients.

Chelmsford, Mass.-based Zoll’s therapy system delivers hyperbaric levels of oxygen directly to damaged heart muscle following successful revascularization through angioplasty and stenting of the blocked coronary artery.

The system is indicated for patients who suffer left anterior descending ST-elevation myocardial infarction (LAD STEMI), the most serious type of heart attack, and are treated within six hours of symptom onset. Zoll touts SSO2 therapy as the first and only FDA-approved device beyond PCI that reduces muscle damage in these kinds of patients.

In March, Zoll won FDA approval for the latest generation of its TherOx system. The company completed the acquisition of Irvine, Calif.-based TherOx and its acute myocardial infarction treatment for an undisclosed amount in June 2019.

“I am very happy to know that ZOLL received CE Mark approval for the TherOx system,” Centro Cardiologico Monzino, University of Milan interventional cardiology director Dr. Antonio Bartorelli said in a news release. “We were among the first in Europe to observe the beneficial impact of SSO2 therapy on left ventricular recovery after primary coronary intervention in patients with LAD ST-elevation myocardial infarction and we look forward to being able to use this effective treatment again in our patients.”

Filed Under: Cardiovascular, Regulatory/Compliance, Structural Heart Tagged With: CE Mark, TherOx Inc, Zoll Medical

More recent news

  • Ambu wins FDA clearance for first single-use cysto-nephroscope
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy